

Editorial on Neuroplasticity and Antipsychotics in Treatment of Schizophrenia

Fandiño-Franky J*

Fundacion Centro Colombiano de Epilepsia y Enfermedades Neurologicas, Colombia, USA

This paper is a deep and fortunate revision of medical literature about causes of schizophrenia and some future treatment of this controversial disease. The author carries the lector to the concept of neuroplasticity, the roll of Dopamine and GABA, as well as the excitatory glutamate over the dorsolateral prefrontal cortex of the brain, where he sustains (with important literature) reside the crucial anatomico-physiological part of the brain for schizophrenia. Very interesting aspects are explained, based on studies performed since 2000 by Elvevag [1], over presented brain atrophy in schizophrenia due to neurotoxicity and neurodegeneration “that involved loss of neurons in the gray matter with marked reduction in the number and size of dendritic extensions”. The author tries to explain after Wakade’s [2] investigations that haloperidol produces neurotoxicity and cell

apoptosis opposite to second generation antipsychotics that stimulate neurogenesis.

I found a weak aspect in this interesting paper. There are no personal researches and it looks as monograph more than a real research study. This diminishes a little the importance of the paper. Nevertheless it can be very useful for students and researchers who need pharmacological references.

References

1. Elvevåg B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. *Crit Rev Neurobiol* 14: 1-21.
2. Wakade CG, Mahadik SP, Waller JL, Chiu FC (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. *J Neurosci Res* 69: 72-79.

*Corresponding author: Jaime Fandiño-Franky, Fundacion Centro Colombiano de Epilepsia y Enfermedades Neurologicas, Colombia, USA, Tel: 5756618199; E-mail: fandinojaime@gmail.com

Received May 24, 2015; Accepted May 26, 2015; Published May 29, 2015

Citation: Fandiño-Franky J (2015) Editorial on Neuroplasticity and Antipsychotics in Treatment of Schizophrenia. *J Neurol Disord* 3: e115. doi: [10.4172/2329-6895.1000e115](https://doi.org/10.4172/2329-6895.1000e115)

Copyright: © 2015 Fandiño-Franky J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.